早期乳がんにおける補完療法:東南ヨーロッパの症例調査における腫瘍内科医の科学的根拠に基づく意思決定
Teo Buhovac1, Žarko Bajić2, Mario Nalbani3
1Oncology Clinic, University Clinical Hospital Mostar, Faculty of Medicine, University of Mostar, Mostar, Bosnia and Herzegovina.
Abstract:
Complementary therapies are increasingly integrated into the framework of integrative oncology. While numerous complementary therapies provide potential benefits, some may also carry risks, including interactions with conventional cancer treatments. The degree to which oncologists' real-world decisions regarding complementary therapies align with evidence-based guidelines remains uncertain. This study aimed to evaluate oncologists' evidence-based decisions on whether specific complementary therapies should be prohibited, permitted, or recommended for early breast cancer treatment. We conducted a cross-sectional online survey that included a randomized vignette experiment involving oncology specialists and residents from seven Southeast European countries. The primary outcome was the percentage of accurate classifications of 28 therapy-indication pairs in neoadjuvant and adjuvant settings, benchmarked against published evidence. Correctness was assessed using both a strict definition (one correct option) and an expanded definition (accepting "allow" or "recommend" when supported by evidence). A total of 136 respondents met the inclusion criteria and provided paired responses. Median accuracy was found to be 52% (95% CI 48-55) under the strict definition and 70% (95% CI 67-72) under the expanded definition, with no significant differences observed between neoadjuvant and adjuvant settings. Evidence-based therapies, such as physical exercise and cognitive behavioral therapy, were most frequently recommended, whereas most other therapies received endorsement from fewer than 25% of respondents. Overall, oncologists exhibited moderate alignment with evidence, demonstrating a tendency to permit rather than actively recommend complementary therapies, even when evidence indicated potential benefits and safety. These findings underscore the necessity for targeted educational interventions aimed at enhancing oncologists' understanding and ensuring the safe and informed integration of complementary therapies into clinical practice.
関連する概念動画
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Survival Analysis
Treatment Resistant Cancers
Tumor Immunotherapy
